Latest sources have revealed the fact that Moleculin Biotech Inc. (NASDAQ:MBRX) has finally signed an agreement with MD Anderson Cancer Center. The follows their deal which involved the Leukemia Drug called Annamycin. The signing of this agreement had some underlying deals which includes licensing agreement. Apparently, Moleculin is signing a new technology agreement with MD Anderson Cancer Centre. The agreement will be based on the new patient application; an application which its intend is to file any data relating to Annamycin drug use, order and distribution as far as the treatment of relapse or refractory acute myeloid leukemia (AML) is concerned.
Key Patent Issues Expected to Resolve with New Agreement
According to different sources; based on an interview with Moleculin CEO, Walter Klemp, it is now crystal clear that the new agreement is based on the statement from the CEO, which said, “In anticipation of beginning our planned clinical trials for Annamycin, one of our priorities has been to use the best possible protection for our intellectual property” In addition, the CEO said, “ Some key patent applications had yet to be filed and signing a new license agreement with MD Anderson clears the way for those patents”
Benefits to be Accrued from Collaborating with MD Anderson
From the look of things and from the different perspectives expressed by different sources, it is a fact that with MD Anderson on board, Moleculin Company will be in a position to gain ground because of the fact that the issues associated with patent rights have been resolved by MD Anderson. With MD Anderson on board, Moleculin will also be able to manufacture its new drug and distribute it through the MD Anderson distribution chains without the need to worry about patent issues and licensing in the long run. Considering that Moleculin has done a series of clinical trials on the new drug, MD Anderson being a Center for Cancer Treatment will make the use of drug as more efficient.
With the signing of the agreement with MD Anderson Cancer Center, Moleculin is now is a good position to benefit from the collaboration. This has been echoed by Moleculin CEO, Klemp who said, “We have benefited greatly from our collaboration with MD Anderson and this license helps ensure that collaboration continues”
Moleculin Biotech stocks closed yesterday’s session at $2.18 which was an improvement of $0.17 or 8.46%.
